|
TODAY'S HEADLINES
Doctors and other health care providers should stop subcutaneous injection use of Expression by Enhancement Medical LLC, the Food and Drug Administration (FDA)announced this week. It is not approved as a dermal filler. » Adverse events associated
|
ADVERTISEMENT
Insights into managing atopic dermatitis and acne
Atopic dermatitis and acne have significant physical, psychosocial and financial impacts on patients. Keep current on the epidemiology and pathogenesis of both conditions and how these may impact patient care.
 Read More.
|
|
The U.S. House of Representatives has passed a bill that would streamline the approval process for over-the-counter sunscreen products. » Find out more
|
|
The human monoclonal antibody dupilumab has shown promising results in treating moderate-to-severe atopic dermatitis in a series of phase 2 studies. » See the study results
|
|
In part two of this series, we look at tax, investment and insurance mistakes physicians make when following advice aimed at average Americans. » Are you using these strategies?
|
|
|
Like
Tweet
